Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α
| Autor: | Marie Klinge Brimnes, Hans Carl Hasselbalch, Caroline Hasselbalch Riley, Ole Weis Bjerrum, Per thor Straten, Inge Marie Svane, Morten K. Jensen |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male Immunology Clone (cell biology) Alpha interferon Antineoplastic Agents Interferon alpha-2 T-Lymphocytes Regulatory Biochemistry Immune system Polycythemia vera Myeloproliferative Disorders T-Lymphocyte Subsets Humans Hydroxyurea Medicine IL-2 receptor Polycythemia Vera Aged business.industry Interleukin-2 Receptor alpha Subunit Interferon-alpha Cancer FOXP3 Forkhead Transcription Factors Cell Biology Hematology Middle Aged medicine.disease Recombinant Proteins Primary Myelofibrosis Female business Thrombocythemia Essential |
| Zdroj: | Blood. 118:2170-2173 |
| ISSN: | 1528-0020 0006-4971 |
| Popis: | Recent reports have described complete or major molecular remission in patients with polycythemia vera after long-term treatment with the immunomodulatory agent IFN-α2. Accordingly, there are reasons to believe that the immune system is a key player in eradicating the JAK2 mutated clone in these patients. Foxp3+ regulatory T cells play a pivotal role in maintaining immune homeostasis and, importantly, preventing immune reactivity to self-antigens; however, their suppressive activity can compromise an effective antitumor immune response, and high frequencies of regulatory T cells in peripheral blood have been reported in both hematologic and solid cancers. We have analyzed the number, phenotype, and function of circulating CD4+CD25+Foxp3+ T cells in patients with chronic myeloproliferative neoplasms. Surprisingly, we found a marked expansion of this subset of lymphocytes in patients treated with IFN-α2 (13.0%; 95% confidence interval [CI] 10.8% to 15.2%) compared with healthy donors (6.1%; 95% CI 4.9% to 7.2%), patients with untreated chronic myeloproliferative neoplasms (6.9%; 95% CI 5.8% to 7.4%), or patients treated with hydroxyurea (5.8%; 95% CI 4.3% to 7.4%; P < .0001). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|